Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.68 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.68 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | GRM6 | O15303 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | GRM8 | O00222 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | GRM5 | P41594 | 1/20 | 0.68 |
| ▸ | MTOR | P42345 | 1/20 | 0.68 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.68 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063416 | 1.00 | CYP1A2 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL1064244 | 1.00 | CYP1A2 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL719389 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL4835874 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL179741 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL481144 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL2157698 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL935371 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL235442 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 | |
| SCHEMBL3125919 | 0.81 | GRM4 (1.00) | CYP1A2ALOX15ALDH1A1KDM4EGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552733-B2 | Terpenophenolic compounds and their use | PHYTOTHERAPEUTIX LIMITED (GB) | 2026-02-17 | — | — | US | claimed |
| US-20230225985-A1 | TERPENOPHENOLIC COMPOUNDS AND THEIR USE | PHYTOTHERAPEUTIX LIMITED (GB) | 2023-07-20 | — | — | US | claimed |
| US-20230227390-A1 | TERPENOPHENOLIC COMPOUNDS AND THEIR USE | PHYTOTHERAPEUTIX LIMITED (GB) | 2023-07-20 | — | — | US | claimed |
| CN-116194431-A | Terpene phenol compound and application thereof | 植物疗法有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-101981050-A | New blood coagulation factor inhibitors | NOVO NORDISK HEALTHCARE AG | 2011-02-23 | — | — | CN | claimed |
| EP-1952797-A1 | Use of a cosmetic composition comprising NMDA receptor agonists for cosmetic skin treatment | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2008-08-06 | — | — | EP | claimed |
| EP-1800672-A1 | Pharmaceutical composition and the use therof for the treatment of dermatoses | Dr. August Wolff GmbH & Co. (DE) | 2007-06-27 | — | — | EP | claimed |
| US-12606508-B2 | Cannabis extracts and uses thereof | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2026-04-21 | — | — | US | disclosed |
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | UNIV OXFORD INNOVATION LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12552733-B2 | Terpenophenolic compounds and their use | PHYTOTHERAPEUTIX LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4662489-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | Oxford University Innovation Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| EP-4626438-A2 | INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS | Pinata Holdings Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025022003-A1 | BETA-PEPTIDES WITH CYTOTOXIC ACTIVITY ON CANCER CELLS | Universität Linz (AT) | 2025-01-30 | — | — | WO | disclosed |
| US-5919628-A | Amino acid transporters and uses | OREGON HEALTH SCIENCES UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5840516-A | SCREENING COMPOUNDS AS AN INHIBITOR OF EXCITATORY AMINO ACID TRANSPORT IN CELLS, TRANSFORMING CELL CULTURE FOR GENETIC EXPRESSION, ANALYZING TRANSFORMED CELL CULTURE | STATE OF OREGON (US) | 1998-11-24 | — | — | US | disclosed |
| US-5776774-A | Amino acid transporters and uses | STATE OF OREGON (US) | 1998-07-07 | — | — | US | disclosed |
| US-5658782-A | AN ISOLATED NUCLEIC ACID COMPRISING A NUCLEOTIDE SEQUENCE ENCODING A HUMAN EXCITATORY AMINO ACID TRANSPORTER PROTEIN; GENETIC ENGINEERING | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY A NON-PROFIT ORGANIZATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0610336-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS BY AN INTERLEUKIN-1 INHIBITING COMPOUND | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993008820-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS BY AN INTERLEUKIN-1 INHIBITING COMPOUND | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993008819-A1 | TREATMENT OF NEUROLOGICAL CONDITIONS BY AN INTERLEUKIN-1 INHIBITING COMPOUND | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | MAX, NPPA, NUP210 | CYP1A2 4846/4885ALOX15 4473/4885ALDH1A1 4882/4885 |
| US-20230225985-A1 | TERPENOPHENOLIC COMPOUNDS AND THEIR USE | TPMT, MALT1, UGT1A1 | CYP1A2 42/4885ALOX15 1873/4885ALDH1A1 484/4885 |
| US-12606508-B2 | Cannabis extracts and uses thereof | CNR1, CNR2, FAAH | CYP1A2 364/4885ALOX15 604/4885ALDH1A1 723/4885 |
| US-20230227390-A1 | TERPENOPHENOLIC COMPOUNDS AND THEIR USE | TPMT, MALT1, UGT1A1 | CYP1A2 43/4885ALOX15 1935/4885ALDH1A1 484/4885 |
| US-12552733-B2 | Terpenophenolic compounds and their use | TPMT, MALT1, CNR1 | CYP1A2 70/4885ALOX15 2151/4885ALDH1A1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.